Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
arGEN-X
Biotech
Argenx files for IPO to take autoimmune drug to phase 3
Argenx has filed to raise up to $75 million in a Nasdaq IPO to take lead candidate ARGX-113 to the cusp of a pivotal trial.
Nick Paul Taylor
Apr 24, 2017 5:13am
EuroBiotech: More Articles of Note
Mar 2, 2017 9:47am
Fresh from AbbVie deal, argenx sees revenue growth but cuts two R&D collabs
Aug 26, 2016 8:05am
Fresh from its AbbVie cancer pact, argenx raises $33M with U.S. investors
Jun 3, 2016 3:45am
AbbVie, argenx sign $685M preclinical immuno-oncology deal
Apr 21, 2016 3:01am
